Abstract
Trichomoniasis, a widespread sexually transmitted infection caused by Trichomonas vaginalis, affects approximately 278 million individuals annually.
OG Article: here
View our Fair Use Policy: here
Treatment challenges arise from resistance to the current therapy, Metronidazole (MTZ), and its associated side effects.
Cannabis sativa, which contains over 100 phytocannabinoids, has gained increasing attention for its therapeutic applications, including anti-parasitic properties. With growing global acceptance and legalization, cannabis research has expanded significantly.
This study investigates the anti-parasitic effects of cannabinoids—specifically WIN 55,212–2 (WIN) and Cannabivarin (CBV)—on the growth and morphology of T. vaginalis.
Additionally, the pharmacokinetic properties of these cannabinoids were evaluated.
Notably, CBV demonstrated compliance with Lipinski's rules, suggesting its potential suitability for oral drug delivery.
Both cannabinoids exhibited inhibitory effects on the growth of T. vaginalis trophozoites and reduced parasite adhesion to host cells.
Morphological changes, including membrane projections, blebbing, autophagosomes, and damaged hydrogenosomes, were observed following treatment.
These findings underscore the need for further investigation into the therapeutic potential of cannabinoids and their mechanisms of action against T. vaginalis.
Comments